A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.

Felip, Enriqueta; Brunsvig, Paal; Viñolas, Núria; Aix, Santiago Ponce; Costa, Enric Carcereny; Gómez, M. Dómine; Pérez, Jose; Arriola, Edurne; Campelo, Rosario García; Spicer, James; Thompson, Jonathan R.; Granados, A.L. Ortega; Holt, Robert J.; Lorens, K; Lorens, James B.; Shoaib, Muhammad; Siddiqui, A.; Schmidt, Emmett V.; Chisamore, Michael; Krebs, Matthew

doi:10.1200/jco.2019.37.15_suppl.9098

Cited by 18 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 right panel). Indeed, in a recent clinical trial NCT03184571, the combination of AXL inhibitor and anti-PD1 has shown promising efficacy among AXL-positive non-small cell lung cancer patients [10]. Hence, this module can prioritize genes with the best potential for developing combination immunotherapies.…”

Section: Gene Set Prioritization Modulementioning

confidence: 99%

Large-scale public data reuse to model immunotherapy response and resistance

et al. 2020

View full text Add to dashboard Cite

Despite growing numbers of immune checkpoint blockade (ICB) trials with available omics data, it remains challenging to evaluate the robustness of ICB response and immune evasion mechanisms comprehensively. To address these challenges, we integrated large-scale omics data and biomarkers on published ICB trials, nonimmunotherapy tumor profiles, and CRISPR screens on a web platform TIDE (http://tide.dfci.harvard.edu). We processed the omics data for over 33K samples in 188 tumor cohorts from public databases, 998 tumors from 12 ICB clinical studies, and eight CRISPR screens that identified gene modulators of the anticancer immune response. Integrating these data on the TIDE web platform with three interactive analysis modules, we demonstrate the utility of public data reuse in hypothesis generation, biomarker optimization, and patient stratification.

show abstract

Section: Gene Set Prioritization Modulementioning

confidence: 99%

Large-scale public data reuse to model immunotherapy response and resistance

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The metabolic changes associated with M1/M2 polarization may also regulate activation state (196,197). Much like the distinct glutaminase-dependent differentiations of Th17 and Th1 T cells to regulate the immune response (198), direct metabolic changes in macrophages, or the output of altered metabolism, can affect M1/M2 polarization.…”

Section: Manipulating Macrophage Metabolism To Increase M1 Polarizationmentioning

confidence: 99%

Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes

et al. 2021

View full text Add to dashboard Cite

Macrophages are a specialized class of innate immune cells with multifaceted roles in modulation of the inflammatory response, homeostasis, and wound healing. While developmentally derived or originating from circulating monocytes, naïve macrophages can adopt a spectrum of context-dependent activation states ranging from pro-inflammatory (classically activated, M1) to pro-wound healing (alternatively activated, M2). Tumors are known to exploit macrophage polarization states to foster a tumor-permissive milieu, particularly by skewing macrophages toward a pro-tumor (M2) phenotype. These pro-tumoral macrophages can support cancer progression by several mechanisms including immune suppression, growth factor production, promotion of angiogenesis and tissue remodeling. By preventing the adoption of this pro-tumor phenotype or reprogramming these macrophages to a more pro-inflammatory state, it may be possible to inhibit tumor growth. Here, we describe types of tumor-derived signaling that facilitate macrophage reprogramming, including paracrine signaling and activation of innate immune checkpoints. We also describe intervention strategies targeting macrophage plasticity to limit disease progression and address their implications in cancer chemo- and immunotherapy.

show abstract

“…For AXL-positive patients, the ORR was 40%. The median PFS was 4.0 months and 5.9 months for AXL-positive patients [70].…”

Section: Axl Kinase Inhibitormentioning

confidence: 99%

Emerging therapeutic agents for advanced non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first inhuman or early-phase I/II clinical trials. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. Finally, we present a brief review of the emerging agents and ongoing clinical studies.

show abstract

A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.

Cited by 18 publications

References 0 publications

Large-scale public data reuse to model immunotherapy response and resistance

Large-scale public data reuse to model immunotherapy response and resistance

Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes

Emerging therapeutic agents for advanced non-small cell lung cancer

Contact Info

Product

Resources

About